Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/6/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
(NYSE: RCUS) Delayed: 29.66 -0.47 (1.56%)
Previous Close $30.13    52 Week High $ 
Open $29.64    52 Week Low $ 
Day High $30.10    P/E N/A 
Day Low $29.40    EPS $ 
Volume 736,983